Cellectar Biosciences (CLRB) Research & Development (2010 - 2026)
Cellectar Biosciences (CLRB) posted Research & Development of $3.2 million for Q4 2025, up 25.18% sequentially from $2.5 million in Q3 2025, and down 49.13% YoY from $6.2 million in Q4 2024.
Cellectar Biosciences (CLRB) Research & Development (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Research & Development for 16 years, with the latest figure at $3.2 million in Q4 2025.
- Quarterly Research & Development fell 49.13% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.5 million (down 56.0% YoY) and the FY2025 annual result came in at $11.5 million, down 56.0% from the prior year.
- Research & Development advanced to $3.2 million in Q4 2025 per CLRB's latest filing, from $2.5 million in the prior quarter.
- Over five years, Research & Development peaked at $7.7 million in Q4 2023 and troughed at $2.4 million in Q2 2025.
- A 5-year average of $5.0 million and a median of $4.6 million in 2021 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2025: Research & Development surged 87.7% in 2021, then sank 67.47% in 2025.
- Over 5 years, Research & Development stood at $4.4 million in 2021, then grew by 2.55% to $4.5 million in 2022, then surged by 71.95% to $7.7 million in 2023, then retreated by 19.75% to $6.2 million in 2024, then slumped by 49.13% to $3.2 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $3.2 million, $2.5 million, and $2.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.56 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 6.21 Mn |
| Sep 30, 2024 | 5.49 Mn |
| Jun 30, 2024 | 7.35 Mn |
| Mar 31, 2024 | 7.09 Mn |
| Dec 31, 2023 | 7.74 Mn |
| Sep 30, 2023 | 7.03 Mn |
| Jun 30, 2023 | 6.14 Mn |
| Mar 31, 2023 | 6.36 Mn |
| Dec 31, 2022 | 4.50 Mn |
| Sep 30, 2022 | 5.21 Mn |
| Jun 30, 2022 | 4.14 Mn |
| Mar 31, 2022 | 3.70 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | 3.94 Mn |
| Jun 30, 2021 | 4.63 Mn |